Trial Profile

A clinical trial of KB103 for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Beremagene geperpavec (Primary)
Indications Epidermolysis bullosa; Epidermolysis bullosa dystrophica
Focus Therapeutic Use
Sponsors Krystal Biotech

Most Recent Events

08 Aug 2019 New trial record
05 Aug 2019 According to an Krystal Biotech Media release, a clinical trial of KB103 in EU is expected to initiate in first half of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com